NCT03636503 2025-02-06Rituximab + Immunotherapy in Follicular LymphomaDana-Farber Cancer InstitutePhase 1 Terminated24 enrolled 25 charts
NCT01307267 2020-03-17A Study Of PF-05082566 As A Single Agent And In Combination With RituximabPfizerPhase 1 Completed190 enrolled 65 charts